The efficacy of clopidogrel therapy in patients with an acute coronary syndrome (ACS) has been established using the clopidogrel hydrogen sulfate (CHS) formulation. We compared the antiplatelet effectiveness of long-term administration of the original CHS with a generic clopidogrel besylate (CB) salt formulation in 86 patients with a history of an ACS. At 1 month after the episode, patients receiving 75 mg/d CHS were randomized to continue with CHS (n = 41) or to switch to 75 mg/d CB (n = 45). Platelet aggregation, vasodilator-stimulated phosphoprotein (VASP) phosphorylation, P-selectin expression, and platelet–leucocyte conjugates were determined before randomization and at 6 months afterward. No difference in any platelet parameter studied was observed between the 2 groups either before randomization or after 6 months of treatment with CHS or CB. We conclude that there is no difference in the antiplatelet efficacy between CB and CHS during long-term administration in patients with a history of an ACS.
DaviGPatronoC. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24):2482–2494.
2.
Antithrombotic Trialists' Collaboration.. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.
3.
GachetC. P2 receptors, platelet function and pharmacological implications. Thromb Haemost. 2008;99:466–472.
4.
SabatineMSCannonCPGibsonCM. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179–1189.
5.
ChenZMJiangLXChenYP. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607–1621.
6.
FoxKAMehtaSRPetersR. Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004;110(10):1202–1208.
7.
YusufSMehtaSRZhaoF. Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 2003;107(7):966–972.
8.
QuinlanDJEikelboomJWGoodmanSG. Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. Eur Heart J. 2011;32(18):2256–2265.
9.
BonelloLTantryUSMarcucciR. Working Group on High On-Treatment Platelet Reactivity Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919–933.
10.
SofiFMarcucciRGoriAMGiustiBAbbateRGensiniGF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost. 2010;103(4):841–848.
11.
Sung-DooKWonkuKHaeWon L. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. Clin Ther. 2009;31(4):793–800.
12.
NeubauerHKrugerJCLaskS. Comparing the antiplatelet effect of clopidogrel hydrogen sulfate and clopidogrel besylate: a crossover study. Clin Res Cardiol. 2009;98(9):533–540.
13.
GarberMCNauDPEricksonSRAikensJELawrenceJB. The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care. 2004;42(7):649–652.
14.
MitsiosJVPapathanasiouAIRodisFIElisafMGoudevenosJATselepisAD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation. 2004;109(11):1335–1338.
15.
SchwarzURGeigerJWalterUEigenthalerM. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets—definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost. 1999;82(3):1145–1152.
16.
KalantziKIDimitriouAAGoudevenosJATselepisAD. The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within one month of treatment. Platelets. 2011;[Epub ahead of print]
17.
BonelloLCamoin-JauLArquesS. Adjusted clopidogrel loading doses according to vasolidator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol. 2008;51(14):1404–1411.
18.
KalantziKIDimitriouAAMilionisHJGoudevenosIATselepisAD. Clopidogrel differentially affects platelet-mediated thrombosis and inflammatory response in patients with acute coronary syndromes. J Thromb Haemost. 2011;9(4):875–878.
19.
AleilBJacqueminLDe PoliF. ‘‘Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) Randomized Study. JACC Cardiovasc Interv. 2008;1(6):631–638.
20.
von BeckerathNKastratiAWieczorekA. A double- blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J. 2007;28(15):1814–1819.
21.
PalmeriniTBarozziCTomasiL. A randomised study comparing the antiplatelet and antinflammatory effect of clopidogrel 150mg/day versus 75mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE study. Thromb Res. 2010;125(4):309–314.
22.
StoreyRFJudgeHMWilcoxRGHeptinstallS. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost. 2002;88(3):488–494.
23.
XiaoZTherouxP. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol. 2004;43(11):1982–1988.
